Naegis Pharmaceuticals Inc.
Vancouver · British Columbia, Canada corporation · 1 known investors
Naegis Pharmaceuticals is a retina-focused ophthalmology company developing oral and topical small-molecule therapies that inhibit both LTB4 and cysteinyl leukotrienes as non-injection treatments for inflammatory eye diseases such as AMD, diabetic retinopathy, and uveitis. Its lead compound, N0651, is a dual-leukotriene inhibitor advancing into human studies to protect retinal and corneal tissue.</parameter> <parameter name="founders">[{"full_name": "Alan Ridgeway", "title": "Chief Executive Officer"}, {"full_name": "David Burgoyne", "title": "President"}, {"full_name": "Eduardo Navajas", "title": "Chief Medical Officer"}, {"full_name": "Julian Gangolli", "title": "Chairman of the Board"}]</parameter> <parameter name="investors_mentioned">[]
Founders & leadership
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$350.8KraisedMay 2024 · 4 investors · OtherRule 506(b)
- Philip DaviesDirector
- Michael LiggettDirector
- Julian GangolliDirector
- Cameron GroomeDirector
- David BurgoyneExecutive Officer, Director
- Ian McBeathExecutive Officer, Director
- Offering amount
- $350.8K
- Amount sold
- $350.8K
- First sale
- Apr 2024
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.